Crossmark

: MP has received honoraria for participation on advisory boards for AstraZeneca, Eli Lilly, MannKind, Medtronic Diabetes, Pfizer, Sanofi, Dompé, LifeScan, Novo Nordisk, Insulet, Provention Bio, Merck, Ascensia, Bayer, Embecta and Tandem, and as a speaker for Eli Lilly, Medtronic Diabetes, Novo Nordisk, Pfizer, Sanofi and Ascensia. MP owns stocks in DreaMed Diabetes and NG Solutions and his institution has received research grant support from Eli Lilly, Medtronic Diabetes, Novo Nordisk, Pfizer, Sanofi, DreaMed Diabetes, NG Solutions, Dompé, Lumos, GWave, OPKO, Provention Bio, AstraZeneca and Omega Galil, and consulting fees from Qulab Medical and Provention Bio. TB has served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, Medtronic, Abbott and Indigo Diabetes. TB has received honoraria for participating on the speakers bureau of Eli Lilly, Novo Nordisk, Medtronic, Abbott, Sanofi, Dexcom, Aventis, Astra Zeneca and Roche. TB’s institution has received research grant support from Abbott, Medtronic, Novo Nordisk, Sanofi, Novartis, Sandoz, Zealand Pharma, the Slovenian Research and Innovation Agency, the National Institutes of Health and the European Union. REJB is a member of the Provention Bio advisory board and has received a speaker’s honorarium from EASD Rising Stars sponsored by Sanofi and a Superior Novo Nordisk PHD Fellowship. EB has received speaker’s honoraria from Sanofi. HMC has received research grant support from Sanofi, IQVIA, Breakthrough T1D (formerly known as JDRF), Chief Scientist Office, Diabetes UK and the UK Medical Research Council. HMC has received honorarium from Novo Nordisk and owns shares in Roche Pharmaceuticals and Bayer AG. TD has received lecture/other fees and honoraria from Abbott, Astra Zeneca, Boehringer Ingelheim, Dexcom, Eli Lilly, Medtronic, Novo Nordisk, Provention Bio, Roche, Sanofi and Vertex. KD has received honoraria for participation on advisory boards for Medtronic and Novo Nordisk and speaker fees from Abbott, Eli Lilly, Novo Nordisk, Medtronic and Pfizer. OE is a member of the Sanofi and Medtronic Diabetes advisory boards. OE has received research support from Medtronic Diabetes, MannKind Pharmaceutical, Dexcom, Eli Lilly Diabetes, Abbott, Vertex Pharmaceutical and Janssen Pharmaceutical. OE has received consulting and speaker fees from Medtronic Diabetes, Sanofi and Vertex. All financial support from industry for OE has been through his organisation, T1D Exchange. RIGH has received honoraria for speaking from EASD, Eli Lilly, ENCORE, Liberum, Novo Nordisk, Rovi and Boehringer Ingelheim. RIGH has received conference funding from Novo Nordisk and Eli Lilly. OK has received honorarium and lecture fees from the Sanofi advisory board. DMM has received research support from the NIH, Breakthrough T1D (formerly known as JDRF), NSF and Helmsley Charitable Trust and his institution has had research support from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, Tandem and Roche. RWL has received a consultancy fee from Cigna Insurance. AL has received honorarium from Diamyd Medical AB. MJR has received employment/consultancy fees or grants from Sanofi, Provention Bio and Janssen R&D. KMS has received consultancy fees, grants or honorarium from Provention Bio and Sanofi. KMS has been an advisory board member and consultant for Sanofi, received research funding from Protect. EKS has received lecture fees from Medscape, ADA, Health Matters CME and Med Learning Group LLC and employment/consultancy fees from Sanofi and DRI Healthcare. JSS has been a scientific advisory board member for 4Immune, Abvance, ActoBiotics, Avotres, Biomea Fusion, Kriya Therapeutics, Levicure and Quell Therapeutics. JSS has been a data safety board member for Imcyse and Provention Bio and is a board of directors member for Applied Therapeutics and SAB Therapeutics. JSS has been an advisor or consultant for Dexcom, Eli Lilly, Immunomolecular Therapeutics, Novo Nordisk, Remedy Plan Inc, SAB Therapeutics, Sanofi and Shoreline Therapeutics. JSS has shares in or is an option holder for 4Immune, Abvance, Applied Therapeutics, Avotres, Dexcom, Immunomolecular Therapeutics, Levicure, Remedy Plan Inc and SAB Therapeutics. LAD has received research support for their institution from Dompé, Lilly, MannKind, Medtronic, Provention/Sanofi and Zealand and consulting fees from Vertex and Abata. LAD has a patent pending for use of difuoromethylornithine (DFMO). All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

: All coauthors on the original manuscript were given the opportunity to contribute to this response letter. All listed authors were responsible for drafting and reviewing this letter of response. All listed authors approved the final version of the letter submitted for publication.

Document is current

Any future updates will be listed below